Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AZD7762 Alone and with Gemcitabine in Japanese Patients with Advanced Solid Tumors
jRCT2080220802Phase 1
- Sponsor
- AstraZeneca
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AZD-7762 in Nonhematologic neoplasms (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD7762 alone and in combination with gemcitabine and Pharmacokinetics of AZD7762.
02
Drugs
AZD-7762
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080220802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220802.